Journal
SMALL
Volume 17, Issue 46, Pages -Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/smll.202103645
Keywords
cascade reaction; hyperuricemia treatment; nanozyme activity; red blood cell membrane coating; two-dimensional Pd-Ru nanosheets; uricase
Categories
Funding
- National Natural Science Foundation of China [22075233, 21890752, 21721001, 21802109]
- Fundamental Research Funds for the Central Universities [20720200020]
Ask authors/readers for more resources
Nanozyme-based cascade reactions are shown to be an effective strategy for disease treatment, with the designed Pd-Ru/Uricase@RBC nanoreactor demonstrating good stability, long circulation half-life, and the ability to effectively degrade uric acid to treat hyperuricemia. The integration of high-efficiency enzymatic activity, long circulation capability, and good biocompatibility make it a promising alternative for clinical treatment of hyperuricemia.
Nanozyme-based cascade reaction has emerged as an effective strategy for disease treatment because of its high efficiency and low side effects. Herein, a new and highly active two-dimensional Pd-Ru nanozyme is prepared and then integrated with uricase and red blood cell (RBC) membrane to fabricate a tandem nanoreactor, Pd-Ru/Uricase@RBC, for hyperuricemia treatment. The designed Pd-Ru/Uricase@RBC nanoreactor displayed not only good stability against extreme pH, temperature and proteolytic degradation, but also long circulation half-life and excellent safety. The nanoreactor can effectively degrade UA by uricase to allantoin and H2O2 and remove H2O2 by using Pd-Ru nanosheets (NSs) with the catalase (CAT)-like activity. More importantly, the finally produced O-2 from H2O2 decomposition can in turn facilitate the catalytic oxidation of UA, as the degradation of UA is an O-2 consumption process. By integrating the high-efficiency enzymatic activity, long circulation capability, and good biocompatibility, the designed Pd-Ru/Uricase@RBC can effectively and safely treat hyperuricemia without side effects. The study affords a new alternative for the exploration of clinical treatment of hyperuricemia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available